286 related articles for article (PubMed ID: 29134635)
1. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib: First Global Approval.
Syed YY
Drugs; 2017 May; 77(7):799-807. PubMed ID: 28417244
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Lu Y; Yang S; Ho YY; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1054-1068. PubMed ID: 33713359
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
Ji Y; Abdelhady AM; Samant TS; Yang S; Rodriguez Lorenc K
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):855-866. PubMed ID: 32706937
[TBL] [Abstract][Full Text] [Related]
7. An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.
James AD; Schiller H; Marvalin C; Jin Y; Borell H; Roffel AF; Glaenzel U; Ji Y; Camenisch G
Pharmacol Res Perspect; 2020 Jun; 8(3):e00599. PubMed ID: 32524755
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
[No Abstract] [Full Text] [Related]
13. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
14. Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility.
Chung J; Alvarez-Nunez F; Chow V; Daurio D; Davis J; Dodds M; Emery M; Litwiler K; Paccaly A; Peng J; Rock B; Wienkers L; Yang C; Yu Z; Wahlstrom J
J Pharm Sci; 2015 Apr; 104(4):1522-32. PubMed ID: 25641187
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
16. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Samant TS; Yang S; Miller M; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
[TBL] [Abstract][Full Text] [Related]
18. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Groenland SL; Martínez-Chávez A; van Dongen MGJ; Beijnen JH; Schinkel AH; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2020 Dec; 59(12):1501-1520. PubMed ID: 33029704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
